Buy Like Buffett
Watchlist

Flagship explainer

How Pyxis Oncology, Inc. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$13.9M · 100%Cost of revenue$2.4M · 17%Gross profit$11.5M · 83%Operating income−$84.4M · −609%Income before tax−$78.2M · −565%Income tax$1.4M · 10%Net income−$79.6M · −575%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$13.9M100%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
Cost of revenue$2.4M17%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
$11.5M83%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
−$84.4M−609%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
Income before tax−$78.2M−565%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
Income tax$1.4M10%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
−$79.6M−575%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-118532 · filed Mar 23, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full Pyxis Oncology, Inc. analysis at Buy Like Buffett